Does Geisinger Health Plan Cover Eliquis?

How Geisinger Health Plan Lists Eliquis on Its Formulary

Geisinger Health Plan, based in Danville, Pennsylvania, maintains separate formularies for its commercial (employer-sponsored and individual Marketplace) and Medicare Advantage lines of business. Eliquis appears on both, though its tier placement and cost-sharing structure differ by product.

Commercial Plan Formulary Placement

On most Geisinger commercial plans, apixaban is listed as a Tier 3 preferred brand medication. This tier carries a fixed copay or coinsurance that is lower than a Tier 4 (non-preferred brand) drug but higher than generics on Tiers 1 and 2. For a standard employer plan with a three-tier copay design, expect to pay between $35 and $60 per 30-day supply. Plans using coinsurance instead of flat copays often charge 25% to 40% after the deductible, which can push out-of-pocket costs above $100 per month before the manufacturer card is applied.

Medicare Advantage Formulary Placement

Geisinger Gold Medicare Advantage plans generally place Eliquis on Tier 3 as well. Under the 2026 Medicare Part D redesign, the annual out-of-pocket cap dropped to $2,000 for all Part D enrollees, a change that significantly reduces total-year spending on brand-name anticoagulants [1]. During the initial coverage phase, Medicare Advantage copays for Eliquis typically range from $42 to $47 per month. Once a member enters the coverage gap, the manufacturer discount program (required by the Inflation Reduction Act) covers a portion of the cost, reducing the effective price further.

How to Verify Your Specific Plan

Formularies change at least annually, and mid-year updates can shift tier placement. The most reliable verification method is to log into the Geisinger Health Plan member portal, enter "apixaban" or "Eliquis" in the drug search tool, and confirm tier, copay, and any utilization-management flags for your exact plan ID. You can also call Member Services at the number on the back of your insurance card.

Prior Authorization and Utilization Management

Geisinger Health Plan does not require prior authorization for Eliquis on every plan, but certain utilization-management tools may apply. Understanding these rules before filling your prescription prevents delays at the pharmacy counter.

Step Therapy Requirements

Some Geisinger plans enforce step therapy for direct oral anticoagulants (DOACs). Step therapy means you must try a lower-cost alternative (usually warfarin) and document treatment failure or intolerance before the plan will cover Eliquis at the preferred tier. The 2023 American College of Cardiology/American Heart Association (ACC/AHA) atrial fibrillation guideline gives DOACs a Class I recommendation over warfarin for most patients with non-valvular AF, stating that "DOACs are recommended over warfarin in DOAC-eligible patients" [2]. If your clinician believes step therapy is not medically appropriate, they can file a formulary exception request citing this guideline language.

Quantity Limits

A standard quantity limit of 60 tablets per 30-day fill applies to the 5 mg strength (the standard twice-daily dose for AF). For the 2.5 mg strength used in post-hip or post-knee replacement prophylaxis, the limit is typically 60 tablets per fill as well, though the duration of therapy may be shorter (12 days for knee, 35 days for hip per FDA labeling) [3].

Exceptions and Appeals

If Geisinger denies coverage or applies a restriction you believe is inappropriate, federal and state law guarantee your right to appeal. Pennsylvania Act 68 requires insurers to provide an external review process for coverage denials. Your prescriber submits a coverage determination request, and Geisinger must respond within 72 hours for standard requests or 24 hours for urgent (expedited) requests.

What Eliquis Costs with Geisinger Insurance

The price you pay at the pharmacy window depends on your plan design, which pharmacy you use, and whether you apply a manufacturer discount. Out-of-pocket costs vary widely even within the Geisinger network.

Retail Pharmacy Costs

Geisinger Health Plan operates its own pharmacy network through Geisinger pharmacies in central and northeastern Pennsylvania. Filling at an in-network Geisinger pharmacy may yield a lower copay than using an out-of-network retail chain, because Geisinger's integrated delivery model often negotiates tighter pricing internally. For plans with coinsurance, the pharmacy's contracted rate for a 30-day supply of brand Eliquis typically falls between $450 and $520 before insurance, which means 25% coinsurance translates to roughly $112 to $130 out-of-pocket before any copay card offset.

Mail-Order Savings

Most Geisinger plans offer a 90-day mail-order option through their preferred mail pharmacy. Mail-order fills usually cost two copays for a three-month supply, saving roughly 33% compared to three separate retail fills. For a drug with a $47 retail copay, a 90-day mail fill would cost approximately $94 instead of $141.

The Bristol-Myers Squibb/Pfizer Copay Card

The Eliquis manufacturer copay assistance program, funded by the Bristol-Myers Squibb/Pfizer Alliance, can reduce the out-of-pocket cost to as little as $10 per month for commercially insured patients. The card is not available to patients enrolled in any federal healthcare program, including Medicare, Medicaid, or TRICARE [4]. Eligible Geisinger commercial members can enroll at the official Eliquis website or by calling 1-855-ELIQUIS. The card typically covers up to $6,400 per calendar year in copay or coinsurance charges.

Clinical Evidence Supporting Eliquis Coverage

Health plans cover Eliquis because the clinical-trial evidence for apixaban is strong across multiple indications. This evidence base also supports your prescriber's case if a formulary exception is needed.

Atrial Fibrillation: The ARISTOTLE Trial

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to warfarin in patients with non-valvular atrial fibrillation. Apixaban reduced the rate of stroke or systemic embolism by 21% (hazard ratio 0.79, 95% CI 0.66 to 0.95, P=0.01) and lowered major bleeding by 31% (HR 0.69, 95% CI 0.60 to 0.80, P<0.001) compared to warfarin [5]. All-cause mortality was also lower in the apixaban group (3.52% vs. 3.94% per year, HR 0.89, P=0.047).

DVT/PE Treatment: The AMPLIFY Trial

In the AMPLIFY trial (N=5,395), apixaban was non-inferior to standard enoxaparin/warfarin therapy for recurrent venous thromboembolism (2.3% vs. 2.7%, relative risk 0.84, 95% CI 0.60 to 1.18) while reducing major bleeding by 69% (0.6% vs. 1.8%, RR 0.31, 95% CI 0.17 to 0.55, P<0.001) [6]. This bleeding advantage is a primary reason Geisinger and other plans maintain coverage despite the higher acquisition cost relative to warfarin.

VTE Prophylaxis: ADVANCE Trials

The ADVANCE-2 (N=3,057) and ADVANCE-3 (N=5,407) trials established apixaban 2.5 mg twice daily as effective prophylaxis after knee and hip replacement surgery, respectively. In ADVANCE-3, apixaban reduced the composite of VTE and all-cause death by 64% compared to enoxaparin 40 mg daily (1.4% vs. 3.9%, RR 0.36, 95% CI 0.22 to 0.54, P<0.001) [7].

Geisinger-Specific Coverage Pathways

Geisinger Health Plan is unusual among Pennsylvania insurers because it operates within the Geisinger Health integrated system. This structure creates a few coverage pathways that are specific to its membership.

Geisinger 65 Forward Plans

Geisinger's 65 Forward Medicare Advantage plans, which include dedicated primary-care centers for members age 65 and older, often have simplified drug formularies with lower copays for cardiovascular medications. Members enrolled in 65 Forward should verify whether Eliquis carries a preferred copay tier in their specific plan document, as these plans sometimes negotiate tier placement that differs from standard Geisinger Gold offerings.

Geisinger Family Health Plan (CHIP/Medicaid)

For members on the Geisinger Family plan (Pennsylvania CHIP or Medicaid managed care), Eliquis coverage follows the state Medicaid preferred drug list (PDL). Pennsylvania Medicaid currently covers apixaban, but prior authorization is required, and the prescriber must document the indication and confirm that the patient does not have a mechanical heart valve or moderate-to-severe mitral stenosis (both contraindications for DOAC use per ACC/AHA guidelines) [2].

Employer-Sponsored Custom Formularies

Large employer groups contracting with Geisinger Health Plan may negotiate custom formularies. A custom formulary could place Eliquis on a different tier or waive step therapy entirely. If your employer offers a Geisinger plan and the standard formulary lookup does not match your experience at the pharmacy, contact your HR benefits team to confirm whether a custom drug list applies.

How to Lower Your Eliquis Cost on Geisinger

Even with insurance, brand-name DOACs carry meaningful out-of-pocket costs. Several strategies can reduce what you pay.

Apply the Manufacturer Copay Card First

For commercial Geisinger members, the BMS/Pfizer copay card stacks on top of your insurance benefit. Present both your Geisinger insurance card and the copay card at the pharmacy. The copay card pays the difference between your plan's copay/coinsurance and $10.

Request a Tier Exception

If Eliquis sits on a non-preferred tier in your specific plan, your prescriber can submit a tier exception request. The request must include clinical justification, typically a letter stating that warfarin is contraindicated or not tolerated, or that guideline evidence favors apixaban for your condition. The ACC/AHA 2023 AF guideline and the CHEST 2024 antithrombotic guideline both recommend DOACs over warfarin as first-line therapy for eligible patients [2][8].

Use a Geisinger In-Network Pharmacy

Filling at a Geisinger-owned pharmacy rather than an out-of-network retail chain may reduce your copay by $5 to $15 per fill, depending on your plan's differential copay structure.

Consider 90-Day Mail Order

Switching to 90-day mail-order fills saves one copay per quarter. Over a full year, this adds up to a savings of roughly $140 to $180 for a drug in the $45 to $60 retail copay range.

Track Your Out-of-Pocket Maximum

Under ACA-compliant Geisinger plans, all copays and coinsurance for covered drugs count toward your annual out-of-pocket maximum. For 2026, the ACA out-of-pocket limit is $9,200 for individual coverage [9]. Once you reach this threshold, your plan pays 100% of covered costs for the rest of the year, including Eliquis.

When Geisinger May Not Cover Eliquis

There are a limited number of scenarios in which Geisinger Health Plan may deny or restrict coverage.

Off-Label Use Without Supporting Evidence

Geisinger follows FDA-approved indications and major compendia for coverage decisions. If Eliquis is prescribed for an indication not in the FDA label or not supported by a recognized compendium (such as left ventricular thrombus, which has growing but not yet guideline-endorsed evidence), the plan may deny the claim. Your clinician can submit a prior authorization with supporting literature to request an exception.

Mechanical Heart Valves

Apixaban is contraindicated in patients with mechanical prosthetic heart valves. The RE-ALIGN trial (which tested dabigatran, another DOAC, in mechanical valve patients) was stopped early due to excess thromboembolic and bleeding events [10]. All DOAC labels carry this contraindication, and Geisinger will not cover Eliquis for this patient population. Warfarin remains the standard of care.

Non-Formulary Plan Designs

A small number of legacy Geisinger employer plans may use a closed formulary that excludes Eliquis entirely in favor of warfarin or rivaroxaban. These plans are uncommon, but if you encounter a "not covered" denial, ask your HR team whether a formulary exception pathway exists.

Apixaban Generic Timeline

No generic apixaban is available in the United States as of May 2026. The BMS/Pfizer patent portfolio for Eliquis was originally set to expire in 2026, but litigation settlements with generic manufacturers established staggered launch dates. The earliest expected generic entry is late 2026 to early 2027, based on settlement terms disclosed in SEC filings [11]. When generics reach the market, Geisinger will likely move them to Tier 1 or Tier 2, reducing copays to $0 to $15 for most members.